Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: The atherosclerosis risk in communities study

Journal of the American Heart Association

Volumn 3, Issue 5, 2014, Pages

  Alonso, Alvaro ^a   Misialek, Jeffrey R ^a   Eckfeldt, John H ^b   Selvin, Elizabeth ^c   Coresh, Josef ^c   Chen, Lin Y ^b   Soliman, Elsayed Z ^d   Agarwal, Sunil K ^c   Lutsey, Pamela L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Epidemiology; Kidney; Risk factors

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHILD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; AGE DISTRIBUTION; AGED; ATRIAL FIBRILLATION; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPARATIVE STUDY; GENETICS; HEALTH SURVEY; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX RATIO; UNITED STATES;

AGE DISTRIBUTION; AGED; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BIOMARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; UNITED STATES;

EID: 84928503017     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001082     Document Type: Article

References (32)

1. Heine GH, Seiler S, Fliser D. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant. 2012;27:3072-3081.
2. Dominguez JR, Shlipak MG, Whooley MA, Ix JH. Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J Am Soc Nephrol. 2013;24:647-654.
3. Brown JR, Katz R, Ix JH, de Boer IH, Siscovick DS, Grams ME, Shlipak M, Sarnak MJ. Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals. Clin J Am Soc Nephrol. 2014;9:239-246.
4. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, Shlipak MG. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2012;60:200-207.
5. Lutsey PL, Alonso A, Selvin E, Pankow JS, Michos ED, Agarwal SK, Loehr LR, Eckfeldt JH, Coresh J. Fibroblast growth factor-23 and incident coronary heart disease, heart failure and cardiovascular mortality: the Atherosclerosis Risk in Communities (ARIC) Study. J Am Heart Assoc. 2014;3:e000936 doi: 10.1161/JAHA.114.000936.
6. Faul C, Amaral AP, Oskouei B, Hu M-C, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St. John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-o M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-4408.
7. Seiler S, Cremers B, Rebling NM, Fornof F, Jeken J, Kersting S, Steimle C, Ege P, Fehrenz M, Rogacev KS, Scheller B, Bohm M, Fliser D, Heine GH. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left ventricular dysfunction and atrial fibrillation. Eur Heart J. 2011;32:2688-2696.
8. Mathew JS, Sachs MC, Patton KK, Heckbert SR, Hoofnagle AN, Alonso A, Chonchol M, Deo R, Ix JH, Siscovick DS, Kestenbaum BR, De Boer IH. Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation. 2014;130:298-307.
9. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, Soliman EZ, Astor BC, Coresh J. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2011;123:2946-2953.
10. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol. 1989;129:687-702.
11. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158:111-117.
12. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010;159:850-856.
13. Soliman EZ, Prineas RJ, Case D, Zhang Z-M, Goff DC Jr. Ethnic distribution of electrocardiographic predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities Study (ARIC). Stroke. 2009;40:1204-1211.
14. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, Higgins M, Williams OD, Tyroler HA; The ARIC Investigators. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol. 1996;49:223-233.
15. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2008;101:1016-1022.
16. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20-29.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
18. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
19. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M; for the Chronic Renal Insufficiency Cohort. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol. 2012;7:1155-1162.
20. Mirza MAI, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205:385-390.
21. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60:2263-2270.
22. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, Sinner MF, Sotoodehnia N, Fontes JOD, Janssens ACJW, Kronmal RA, Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA, Schnabel RB, Agarwal SK, McManus DD, Ellinor PT, Larson MG, Burke GL, Launer LJ, Hofman A, Levy D, Gottdiener JS, Kääb S, Couper D, Harris TB, Soliman EZ, Stricker BHC, Gudnason V, Heckbert SR, Benjamin EJ. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2:e000102 doi: 10.1161/JAHA.112.000102.
23. Robinson-Cohen C, Hoofnagle AN, Ix JH, Sachs MC, Tracy RP, Siscovick DS, Kestenbaum BR, de Boer IH. Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA. 2013;310:179-188.
24. Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in Medicare patients. J Am Heart Assoc. 2012;1:e002097 doi: 10.1161/JAHA.112.002097.
25. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009;158:629-636.
26. Horio T, Iwashima Y, Kamide K, Tokudome T, Yoshihara F, Nakamura S, Kawano Y. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens. 2010;28:1738-1744.
27. Lopez FL, Agarwal SK, Grams ME, Loehr LR, Soliman EZ, Lutsey PL, Chen LY, Huxley RR, Alonso A. Relation of serum phosphorus levels to the incidence of atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study). Am J Cardiol. 2013;111:857-862.
28. Fukunaga N, Takahashi N, Hagiwara S, Kume O, Fukui A, Teshima Y, Shinohara T, Nawata T, Hara M, Noguchi T, Saikawa T. Establishment of a model of atrial fibrillation associated with chronic kidney disease in rats and the role of oxidative stress. Heart Rhythm. 2012;9:2023-2031.
29. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933-939.
30. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87-92.
31. Siragy HM, Carey RM. Role of the intrarenal renin-angiotensis-aldosteron system in chronic kidney disease. Am J Nephrol. 2010;31:541-550.
32. Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):141-147.